Semaglutide May Protect Kidneys by Reducing Vascular Resistance and Fibrosis in Type 2 Diabetes, Study Finds
Chronic kidney disease (CKD) is among the most serious complications of type 2 diabetes, contributing substantially to kidney failure, cardiovascular events and premature mortality. Although glucagon-like peptide-1 receptor agonists such as semaglutide have demonstrated kidney benefits in clinical outcome trials, the biological mechanisms underlying these effects remain incompletely understood. A new randomised trial published in Nature Medicine provides important insights into how semaglutide may protect kidney structure and function through effects on renal blood vessels, fibrosis and glomerular endothelial cells.
The study, titled “Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial,” was conducted by Katherine R. Tuttle and colleagues as part of the REMODEL trial.
The 52-week, multicentre, randomised, placebo-controlled study enrolled 106 adults with type 2 diabetes and CKD across 28 centres in eight countries. Participants received once-weekly subcutaneous semaglutide, titrated to 1 mg, or placebo in a 2:1 ratio.
The mean age was 65.3 years, mean estimated glomerular filtration rate (eGFR) was 51.1 mL/min/1.73 m², and median urinary albumin-to-creatinine ratio (UACR) was 187.3 mg/g. Nearly all participants were receiving renin–angiotensin system inhibitors, while approximately 40% were taking SGLT2 inhibitors.
Unlike conventional kidney outcome trials, REMODEL investigated mechanisms of kidney protection using advanced magnetic resonance imaging, kidney biopsies, histological examination and molecular profiling.
The investigators reported several important findings.
The three coprimary MRI outcomes-renal oxygenation, global perfusion and tissue inflammation-did not improve significantly with semaglutide compared with placebo.
However, secondary analyses demonstrated a significant reduction in renal artery resistive index, suggesting lower intrarenal vascular resistance (estimated treatment ratio 0.96; 95% CI 0.93–0.99; P=0.008).
Semaglutide was also associated with higher cortical apparent diffusion coefficient measurements, consistent with attenuation of progressive renal fibrosis.
Albuminuria decreased by approximately 40% compared with placebo (estimated treatment ratio 0.60; 95% CI 0.41–0.88), while 24-hour creatinine clearance was higher by an estimated 12 mL/min after 52 weeks.
Additional imaging demonstrated reductions of approximately 25% in perirenal fat and 13% in renal sinus fat.
Importantly, molecular analyses of paired kidney biopsy samples suggested that glomerular endothelial cells were particularly responsive to semaglutide. Investigators observed changes in gene-expression patterns associated with metabolic stress, inflammation and fibrosis, along with fewer immune cells near glomerular endothelial cells in exploratory spatial analyses.
These findings suggest that semaglutide's kidney effects may extend beyond glucose lowering and weight reduction to include improvements in the renal microvascular environment and pathways involved in tissue injury.
However, the findings require cautious interpretation. The trial was relatively small, its coprimary endpoints were negative, and several positive findings arose from secondary or exploratory analyses without adjustment for multiple comparisons. The study was not designed to establish reductions in kidney failure or mortality.
The results complement, rather than replace, evidence from larger clinical outcome trials such as FLOW.
For practising physicians, the study offers a better understanding of the possible biological mechanisms of kidney protection with semaglutide. It also highlights the potential importance of vascular health, inflammation and fibrosis in diabetic kidney disease.
Clinical Message: Semaglutide may protect the diabetic kidney through multiple mechanisms, including reduced renal vascular resistance, attenuation of fibrosis-related changes and improved glomerular endothelial biology. Although REMODEL did not meet its primary imaging endpoints, its secondary findings provide mechanistic support for kidney benefits demonstrated in larger trials. Treatment decisions should continue to rely on established clinical outcome evidence and current guidelines.
Reference:
Tuttle KR, Bjornstad P, Smith C, et al. Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial. Nature Medicine. Published October 1, 2026.
